New combo therapy shows promise against tough colon cancer
NCT ID NCT07156682
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tests a new drug combination (QL1706 plus XELOX) given before surgery for people with stage III colon cancer that is stable (pMMR/MSS). About 21 participants will receive four cycles of treatment, then have surgery. The main goal is to see if the cancer disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu hospital of Shandong University
Jinan, Shandong, 250012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.